Us Bancorp \De\ Arcutis Biotherapeutics, Inc. Transaction History
Us Bancorp \De\
- $78.3 Billion
- Q2 2025
A detailed history of Us Bancorp \De\ transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 62 shares of ARQT stock, worth $913. This represents 0.0% of its overall portfolio holdings.
Number of Shares
62
Previous 119
47.9%
Holding current value
$913
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ARQT
# of Institutions
249Shares Held
124MCall Options Held
642KPut Options Held
197K-
Suvretta Capital Management, LLC New York, NY11.4MShares$168 Million7.82% of portfolio
-
Jennison Associates LLC11.1MShares$164 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$162 Million4.91% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$129 Million8.65% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$127 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $887M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...